Capital World Investors
LAB icon

Capital World Investors’s Standard BioTools LAB Stock Holding History

Capital World Investors’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-800,000
Closed -$5.82M – 504
2016
Q4 		$5.82M Hold
800,000
– – ﹤0.01% 466
2016
Q3 		$6.41M Hold
800,000
– – ﹤0.01% 467
2016
Q2 		$7.22M Hold
800,000
– – ﹤0.01% 461
2016
Q1 		$6.46M Hold
800,000
– – ﹤0.01% 463
2015
Q4 		$8.65M Hold
800,000
– – ﹤0.01% 482
2015
Q3 		$6.49M Buy
+800,000
New +$12.6M ﹤0.01% 493

Other funds holding LAB

LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Capital World Investors's LAB Position: Q1 2017 in Review

Capital World Investors sold out of Standard BioTools (LAB) in Q1 2017, closing a stake of 800,000 shares — an estimated $5.82M sold.

Capital World Investors first reported a position in LAB in Q3 2015 and held it in 6 quarters. The position peaked at $8.65M in Q4 2015. 80 funds tracked by Wall St. Rank hold LAB as of Q1 2017.

  • Capital World Investors reported no remaining Standard BioTools position as of Q1 2017 after selling out during the quarter.
  • Capital World Investors sold 800,000 Standard BioTools shares in Q1 2017, an estimated $5.82M.
  • Capital World Investors first reported a position in Standard BioTools in Q3 2015 and held it in 6 quarters.
  • Capital World Investors's Standard BioTools position peaked at $8.65M in Q4 2015.
  • 80 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2017.

Based on Capital World Investors's 13F filing for Q1 2017, filed 15 May 2017.